Evidence‑Based Cross‑Tapering from Paroxetine to Sertraline

Cross‑Taper Schedule

In adults with major depressive disorder transitioning from paroxetine to sertraline, reduce the paroxetine dose to ≈ 75 % of the current amount during the first week while initiating sertraline at 25 mg daily (morning dosing) to maintain therapeutic coverage and limit withdrawal risk. 1
During weeks 4–6, titrate sertraline upward to a target therapeutic range of 50–200 mg daily, adjusting the dose according to clinical response and tolerability. [1][2]

The standard therapeutic dose window for sertraline in this population is 50–200 mg per day; most patients achieve adequate symptom control within the 50–100 mg range. [2][1]
Sertraline may be taken with or without food; administering the dose in the morning is preferred to reduce the likelihood of insomnia. 2

Assess patients 1–2 weeks after initiating the cross‑taper for emergence of withdrawal symptoms, suicidal ideation, agitation, or atypical behavioral changes, and intervene promptly if needed. 1
Re‑evaluate therapeutic response at 6–8 weeks; if improvement is insufficient, consider dose escalation or alternative treatment strategies. 1
Conduct regular follow‑up (e.g., weekly during the taper) to monitor for common SSRI adverse effects such as sexual dysfunction, gastrointestinal upset (nausea/diarrhea), and other tolerability issues. 2

Paroxetine is associated with a higher incidence of sexual dysfunction compared with sertraline; patients often report improvement in this domain after completing the switch. 1

After achieving remission of a first depressive episode, continue sertraline for a minimum of 4–9 months to consolidate response and reduce relapse risk. 1
For individuals with recurrent depression (≥ 2 episodes), longer‑term or indefinite maintenance therapy with sertraline is recommended to sustain remission. 1